Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo

Journal of Biochemistry

Volumn 144, Issue 3, 2008, Pages 357-362

  Sami, Siraj ^a   Höti, Naseruddin ^b   Xu, Han Mei ^a   Shen, Zilong ^a   Huang, Xiaofeng ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NANJING UNIVERSITY   (China)

Author keywords

Angiogenesis; Cervical cancer; p21; p53; Valproic acid

Indexed keywords

HISTONE H3; PROTEIN P21; PROTEIN P53; VALPROIC ACID; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; FEMALE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROGNOSIS; TUMOR VOLUME; UTERINE CERVIX CANCER; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; DOSE RESPONSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HELA CELLS; HISTONE DEACETYLASES; HISTONES; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; UTERINE CERVICAL NEOPLASMS; VALPROIC ACID;

EID: 55949119320     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvn074     Document Type: Article

References (38)

1. Rossi, A., Ciafre, S., Balsamo, M., Pierimarchi, P., and Santoro, M.G. (2006) Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res. 66, 7678-7685
2. Cogliano, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., and El Ghissassi, F. (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol. 6, 204
3. Gonzalez Martin, A. (2007) Molecular biology of cervical cancer. Clin. Transl. Oncol. 9, 347-354
4. Cinatl, J. Jr., Cinatl, J., Driever, P.H., Kotchetkov, R., Pouckova, P., Kornhuber, B., and Schwabe, D. (1997) Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8, 958-963
5. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G., and Heinzel, T. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J. 20, 6969-6978
6. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A., and Klein, P.S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741
7. Kostrouchova, M., Kostrouch, Z., and Kostrouchova, M. (2007) Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol. (Praha) 53, 37-49
8. Blaheta, R.A., Michaelis, M., Driever, P.H., and Cinatl, J. Jr. (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev. 25, 383-397
9. Yuan, P.X., Huang, L.D., Jiang, Y.M., Gutkind, J.S., Manji, H.K., and Chen, G. (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276, 31674-31683
10. Michaelis, M., Suhan, T., Michaelis, U.R., Beek, K., Rothweiler, F., Tausch, L., Werz, O., Eikel, D., Zornig, M., Nau, H., Fleming, I., Doerr, H.W., and Cinatl, J. Jr. (2006) Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Death Differ. 13, 446-453
11. Einat, H., Yuan, P., Gould, T.D., Li, J., Du, J., Zhang, L., Manji, H.K., and Chen, G. (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23, 7311-7316
12. Brunello, N. (2004) Mood stabilizers: protecting the mood . . . protecting the brain. J. Affect Disord. 79 (Suppl 1), S15-S20
13. Di Daniel, E., Mudge, A.W., and Maycox, P.R. (2005) Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord. 7, 33-41
14. Blaheta, R.A. and Cinatl, J. Jr. (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev. 22, 492-511
15. Blaheta, R.A., Nau, H., Michaelis, M., and Cinatl, J. Jr. (2002) Valproate and valproate-analogues: potent tools to fight against cancer. Curr. Med. Chem. 9, 1417-1433
16. Kopfstein, L. and Christofori, G. (2006) Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol. Life Sci. 63, 449-468
17. Beecken, W.D., Engl, T., Ogbomo, H., Relja, B., Cinatl, J., Bereiter-Hahn, J., Oppermann, E., Jonas, D., and Blaheta, R.A. (2005) Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells. Int. Immunopharmacol. 5, 757-769
18. Naumov, G.N., Akslen, L.A., and Folkman, J. (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779-1787
19. Verhoef, C., de Wilt, J.H., and Verheul, H.M. (2006) Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr. Pharm. Des. 12, 2623-2630
20. Michaelis, M., Michaelis, U.R., Fleming, I., Suhan, T., Cinatl, J., Blaheta, R.A., Hoffmann, K., Kotchetkov, R., Busse, R., Nau, H., and Cinatl, J. Jr. (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol. Pharmacol. 65, 520-527
21. Shu, Q., Antalffy, B., Su, J.M., Adesina, A., Ou, C.N., Pietsch, T., Blaney, S.M., Lau, C.C., and Li, X.N. (2006) Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin. Cancer Res. 12, 4687-4694
22. Rasila, K.K., Burger, R.A., Smith, H., Lee, F.C., and Verschraegen, C. (2005) Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int. J. Gynecol. Cancer 15, 710-726
23. Hoti, N., Chowdhury, W., Hsieh, J.T., Sachs, M.D., Lupold, S.E., and Rodriguez, R. (2006) Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol. Ther. 14, 768-778
24. Parkin, D.M. (2006) The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044
25. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108
26. Bolden, J.E., Peart, M.J., and Johnstone, R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784
27. Chavez-Blanco, A., Segura-Pacheco, B., Perez-Cardenas, E., Taja-Chayeb, L., Cetina, L., Candelaria, M., Cantu, D., Gonzalez-Fierro, A., Garcia-Lopez, P., Zambrano, P., Perez-Plasencia, C., Cabrera, G., Trejo-Becerril, C., Angeles, E., and Duenas-Gonzalez, A. (2005) Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer 4, 22
28. Hoti, N., Ma, J., Tabassum, S., Wang, Y., and Wu, M. (2003) Triphenyl tin benzimidazolethiol, a novel antitumor agent, induces mitochondrial-mediated apoptosis in human cervical cancer cells via suppression of HPV-18 encoded E6. J. Biochem. (Tokyo) 134, 521-528
29. Michaelis, M., Doerr, H.W., and Cinatl, J. Jr. (2007) Valproic acid as anti-cancer drug. Curr. Pharm. Des. 13, 3378-3393
30. Yamashita, Y., Shimada, M., Harimoto, N., Rikimaru, T., Shirabe, K., Tanaka, S., and Sugimachi, K. (2003) Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer 103, 572-576
31. Noh, E.J. and Lee, J.S. (2003) Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2-M transition. Biochem. Biophys. Res. Commun. 310, 267-273
32. Peart, M.J., Tainton, K.M., Ruefli, A.A., Dear, A.E., Sedelies, K.A., O'Reilly, L.A., Waterhouse, N.J., Trapani, J.A., and Johnstone, R.W. (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63, 4460-4471
33. Li, H. and Wu, X. (2004) Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem. Biophys. Res. Commun. 324, 860-867
34. Wu, P., Meng, L., Wang, H., Zhou, J., Xu, G., Wang, S., Xi, L., Chen, G., Wang, B., Zhu, T., Lu, Y., and Ma, D. (2005) Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor. Biochem. Biophys. Res. Commun. 335, 36-44
35. Finzer, P., Kuntzen, C., Soto, U., zur Hausen, H., and Rosl, F. (2001) Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20, 4768-4776
36. Xia, Q., Sung, J., Chowdhury, W., Chen, C.L., Hoti, N., Shabbeer, S., Carducci, M., and Rodriguez, R. (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 66, 7237-7244
37. Orsetti, M., Colella, L., Dellarole, A., Canonico, P.L., Ferri, S., and Ghi, P. (2006) Effects of chronic administration of olanzapine, amitriptyline, haloperidol or sodium valproate in naive and anhedonic rats. Int. J. Neuropsychopharmacol. 9, 427-436
38. Rouaux, C., Panteleeva, I., Rene, F., Gonzalez de Aguilar, J.L., Echaniz-Laguna, A., Dupuis, L., Menger, Y., Boutillier, A.L., and Loeffler, J.P. (2007) Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 27, 5535-5545